BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//UM//UM*Events//EN
CALSCALE:GREGORIAN
BEGIN:VTIMEZONE
TZID:America/Detroit
TZURL:http://tzurl.org/zoneinfo/America/Detroit
X-LIC-LOCATION:America/Detroit
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20070311T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20071104T020000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTAMP:20260111T114049
DTSTART;TZID=America/Detroit:20260122T143000
DTEND;TZID=America/Detroit:20260122T160000
SUMMARY:Workshop / Seminar:Culture\, History and Politics (CHiP)
DESCRIPTION:- January 15: Cho Han\n- January 22: Marni Morse\n- January 29: Jiyeon Lee\n- February 5: Tess Hamilton\n- February 12: Álvaro Cabrera\n- February 19: Jarron Long\n- February 26: Xianni Zhang\n- March 12: Sarah Farr and Christian Castro-Martinez\n- March 19: Danyelle Reynolds\n- March 26: Vanessa Jiménez-Read\n- April 2: Abigail Skalka and Julieta Goldenberg\n- April 9: Eric Freeburg\n- April 16: TBD
UID:143661-21893600@events.umich.edu
URL:https://events.umich.edu/event/143661
CLASS:PUBLIC
STATUS:CONFIRMED
CATEGORIES:Graduate Student
LOCATION:LSA Building - 4147
CONTACT:
END:VEVENT
BEGIN:VEVENT
DTSTAMP:20260112T112056
DTSTART;TZID=America/Detroit:20260122T150000
DTEND;TZID=America/Detroit:20260122T160000
SUMMARY:Workshop / Seminar:Biomedical Engineering (BME 500) Seminar Series
DESCRIPTION:Non-invasive Histotripsy Cancer Treatment: The Road from Bench to Bedside\nAbstract:\nHistotripsy is the first non-invasive\, non-ionizing\, and non-thermal ablation technology that is based on ultrasound and invented by Dr. Xu and her colleagues at the University of Michigan. Imagine ultrasound delivered from outside the body is used to generate bubbles and destroy the target tumor\, without incision or injury. Pre-clinical studies have shown that ultrasound image-guided histotripsy can non-invasively and mechanically disrupt the target tumor into acellular debris while preserving large normal vessels\, nerves\, and bile ducts. Histotripsy tumor acellular debris is absorbed by the body\, resulting in tumor regression and increased survival benefit. Histotripsy induces significant innate and adaptive immune response and abscopal effect (shrinkage of off-target tumors) in murine tumor models. Multi-center clinical trials confirm that histotripsy produces tumor regression and provides evidence of abscopal effect in patients with primary and metastatic liver tumors. In October 2023\, the Edison histotripsy platform (HistoSonics) was approved by FDA for non-invasive treatment of liver tumors. The Edison system is based on the technology licensed from Dr. Xu’s lab and manufactured by HistoSonics\, a company co-founded by Dr. Xu. To Date\, histotripsy has been used to treat 3000 patients with liver tumors in 70+ hospitals. There are ongoing clinical trials in the U.S. and Europe on histotripsy treatment of renal tumors and pancreatic tumors. Dr. Xu will talk about the mechanism and instrumentation of histotripsy\, the latest pre-clinical and clinical progress\, and her journal to bring this technology from bench to bedside. \nBio:\nDr. Zhen Xu is the Li Ka Shing Endowed Professor of Biomedical Engineering\, and Professor of Radiology and Neurosurgery at the University of Michigan\, Ann Arbor\, MI. Her research focuses on ultrasound therapy and imaging. She is a pioneer and world leader of histotripsy. She has developed histotripsy for cancer\, neurological\, and cardiovascular applications. Her work has led to the FDA approval of histotripsy treatment of liver tumors. She has been elected as Fellow of National Academy of Inventors (NAI)\, American Institute of Medicine and Bioengineering (AIMBE)\, and IEEE. She received the IEEE Ultrasonics\, Ferroelectrics\, and Frequency Control (UFFC) Outstanding Paper Award in 2006\, Frederic Lizzi Award from the International Society of Therapeutic Ultrasound (ISTU) in 2015\, Lockhart Memorial Prize for Cancer Research in 2020\, and IEEE Carl Hellmuth Hertz Ultrasonics Award in 2024. She has published 140 peer-reviewed journal papers and has been awarded $50+ millions of external grant funding. She has 36 issued US and international patents. She is a principal investigator of grants funded by NIH\, Office of Navy Research\, American Cancer Association\, and Focused Ultrasound Foundation. She is the co-founder of HistoSonics. HistoSonics is valued at $3 billions through a recent private acquisition.
UID:143705-21893683@events.umich.edu
URL:https://events.umich.edu/event/143705
CLASS:PUBLIC
STATUS:CONFIRMED
CATEGORIES:Basic Science,Biointerfaces,Biology,biomedical,biomedical engineering,Bioninterfaces,Biosciences,Biotechnology,bme,engineer,engineering,Medicine,Michigan Engineering,seminar
LOCATION:Lurie Biomedical Engineering (formerly ATL) - 1130
CONTACT:
END:VEVENT
END:VCALENDAR